Psychedelics – Multimedia

In this episode, Lucy Lawrence interviews Professor Celia Morgan a Professor of Psychopharmacology at the University of Exeter.

In this episode of TSE Explores, Lucy Lawrence speaks to Professor David Nutt an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep.

The Monteggia laboratory at Vanderbilt University has been investigating the molecular mechanisms that underly this rapid action. In this Teach Me in 10, Dr. Monteggia outlines some of the key discoveries that her team have made, particularly in relation to ketamine, neuroplasticity and neuroreceptors.

Interest in the therapeutic potential of psychedelics, having lain relatively dormant in the face of stigma and heavy regulations for decades, has reignited in the last ten years. In this infographic, we review five psychedelics, detailing their structure, mechanism of action and their potential clinical applications.

Treatments using psychedelics are making waves in psychiatric medicine. In this article, we explore the background, mechanisms of action and therapeutic applications of four leading psychedelic drugs.

On this episode, the team take a look at a new study that suggests people's interpretation of the "Hygiene Hypothesis" - that early exposure to some microorganisms protects against allergic disease - might be in need of a cleanup. They also detail some findings on the psychedelic drug psilocybin and its effects on the connections of the mammalian brain. Not to be missed!

Psychedelics are being explored for a myriad of neurological and psychiatric conditions. In this video, Technology Networks speak with Professor David Nutt and Anthony Tennyson from Awakn Life Sciences, a Toronto-based company who focus on the use of psychedelics to treat addiction.

On this week’s Opinionated Science, the team takes a look at the growing potential of psychedelic medicine. In this episode, we take a deep dive into four leading psychedelic compounds: psilocybin, MDMA, ketamine and DMT.

Much of what we know about the cannabis plant and its effects on the human body has only been formally discovered in the past 60 years. A good deal of these pioneering investigations have involved today's Teach Me in 10 guest: Roger Pertwee, an emeritus professor at the University of Aberdeen.

In this episode, the Technology Networks team discusses the rejuvenated field of psychedelic drugs research and how it might provide solutions for enduring mental health disorders.